Daiichi Pharmaceutical Co., Ltd.

Pharmaceutical Company

Mitsunobu Yoshii

Tadashi Shiotani

Shigeo Watabe

Yoshiya Murashima

Akira Takazawa

Tatsuya Tanaka

Toshitaka Nabeshima

A prophylactic and/or therapeutic method for treating a disease caused by mitochondrial functional abnormality, or a disease with mitochondrial functional abnormality, including: administering a prophylactically and/or therapeutically effective amount to a patient in need of such treatment of a medicament including as an active ingredient a substance having a stabilizing effect on mitochondrial membrane by suppressing or eliminating depolarization of mitochondrial membranes which is caused by elevation of intracellular calcium ion concentration, wherein the stabilizing effect on mitochondrial membrane is an action of suppressing or eliminating depolarization of mitochondrial membranes, wherein the depolarization of mitochondrial membranes is caused by elevation of intracellular calcium ion concentration. The disease may be ischemic diseases, toxic diseases, or degenerative diseases. The medicament may be 2-oxo-1-pyrrolidinylacetic acid 2,6-dimethylanilide which acts as a benzodiazepine receptor antagonist.

Mitochondrial membrane stabilizer

A therapeutic or preventive agent for intractable epilepsy comprising as an active ingredient a compound represented by R &mdash;CH CONH&mdash;R (I), wherein R is a phenyl group or a pyridyl group, which may have a substituent and R is a 2-oxo-1-pyrrolidinyl group which may have a substituent.

Remedies or preventives for intractable epilepsy

Inhibitor for narcotic analgesic dependence/resistance acquisition

Growing community of inventors

Tokyo, Japan

Mitsunobu Yoshii